Key Features

Fusion Nutraceuticals LTD was founded in 2007 with the aim of developing sugar alternative products. Fusion has been manufacturing its own sugar free sweeteners since 2008 and has a very experienced management team with a successful track record both as entrepreneurs and in the food industry. Circa €1.2ml has been invested to date by the promoters and private investors.

The founders of the company are Shane Delaney who has over 24 years in the food ingredient business working with Dalgety, Redbook Ingredient Services and was Commercial Director of Micap plc, (UK). Fergus Clarke was 18 years with Applied Materials USA and more recently CEO of Sports Surgery Clinic, Dublin.

They see huge opportunities in the €50bn sweetener market driven by health concerns with a global reach particularly relating to obesity, heart disease and diabetes.

Their SucraPLUS™ range and own label customers include Adsa (UK), Spar (Europe), Aldi (US), Alphanexa (UAE), Valimex (Spain), Nutrifood (Indonesia), Arkopharma (France) and Kelkin (Ireland).  Dunnes Stores are due to stock their products in 2011.

Sales are projected at €1.7m in 2011 rising to €4.9m by 2016.

The Company is also launching its own new patented product (NGRF) for the world market in 2011. This new sugar alternative will look, feel and taste like sugar but without the calories. It is designed to appeal to consumer preferences for more healthy foods. NGRF will target the €50bn world sugar market and will interest global food and drinks manufacturers as well the large industrial market serving a more health conscious consumer.

Advanced discussions have taken place with a major Indian company to manufacture NGRF under licence. Fusion’s technical team are working with the potential licensee on final product trialling. India has a population of 1.15bn and its retail sugar market is estimated to be worth US$6bn.

The plan over the next 5 years is to have approximately 7 licensees to manufacture for the world market.

NGRF’s future income will come from licences fees and Patent related income. Revenues in excess of €16ml are expected from rights, patent and related income up to 2016.

BES Investment Proposal

The Company is raising €750,000 from eligible investors with management investing €70,000.  The new funds will be used for working capital in their existing manufacturing business and also to fund the process to get NGRF to the manufacturing stage (expected June 2011).

The €750,000 investment will entitle new BES Investors to a 25% equity interest in the Company.

Fusion is projecting an investment of €10,000 will return €17,500 at the end of the 5 years and 6 month investment term. This represents an IIR of 26% after tax at the marginal rate.

Investors will have a defined exit. There will be a put and call option agreement with the Company. However Fusion could seek a public listing or be acquired by another food manufacturer.

The minimum investment is €5,000 and maximum under BES is €150,000.

All subscriptions must be completed no later than 31st December 2010 to enable BES investors to claim the tax relief in the 2010 tax year.

For further information and details of the Risk Factors all potential investors must read a copy of the Investment Memorandum.

Director and Professional advisors

Directors

• Shane Delaney (Managing)
• Fergus Clarke (Executive)
• Ian Craigie (Non Executive)
• David Pierce (Non Executive-Designate)

Auditors

• Mazars

Solicitors

• Byrne Wallace & Doherty Ryan & Associates

Bankers

• Ulster Bank

Company Office

• Unit 8, Block 1, Northwood Court, Santry, Dublin 9

Further Information

For a copy of the Information Memorandum please contact:

Ian Craigie,
29 Kildare St,
Dublin 2

Tel 01 6628666
Fax 01 6611568
Email: kildarest29@gmail.com
Company Website: www.fusionnutra.com